Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia

Am J Health Syst Pharm. 2005 Jan 1;62(1):83-7. doi: 10.1093/ajhp/62.1.83.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Body Temperature
  • Drug Administration Schedule
  • Female
  • Filgrastim
  • Granulocyte Colony-Stimulating Factor / adverse effects
  • Granulocyte Colony-Stimulating Factor / chemistry
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Granulocyte-Macrophage Colony-Stimulating Factor / adverse effects
  • Granulocyte-Macrophage Colony-Stimulating Factor / chemistry
  • Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use*
  • Humans
  • Injections, Subcutaneous
  • Inpatients
  • Male
  • Middle Aged
  • Neoplasms / diagnosis
  • Neoplasms / drug therapy
  • Neoplasms / epidemiology
  • Neutropenia / chemically induced*
  • Neutropenia / diagnosis
  • Neutropenia / drug therapy*
  • Prospective Studies
  • Randomized Controlled Trials as Topic
  • Recombinant Proteins
  • Therapeutic Equivalency
  • Treatment Failure

Substances

  • Antineoplastic Agents
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • sargramostim
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Filgrastim